Influence of the Brain-Derived Neurotrophic Factor Gene Polymorphism on Weight Loss Following Intragastric Balloon Intervention: A Cross-Sectional Study
Ahmad Al-Serri,Hessa Al-Janahi,Mohammad Jamal,Dana AlTarrah,Ali Ziyab,Suzanne Al-Bustan
DOI: https://doi.org/10.2147/dmso.s481547
2024-11-27
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Ahmad Al-Serri, 1 Hessa A Al-Janahi, 1 Mohammad H Jamal, 2 Dana AlTarrah, 3 Ali H Ziyab, 4 Suzanne A Al-Bustan 5 1 Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait; 2 Department of Surgery, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait; 3 Department of Social and Behavioral Science, Faculty of Public Health, Kuwait University, Kuwait City, Kuwait; 4 Department of Community Medicine and Behavioral Sciences, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait; 5 Department of Biological Sciences, Faculty of Science, Kuwait University, Kuwait City, Kuwait Correspondence: Ahmad Al-Serri, Human Genetics Unit, Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait, Tel +965 2463 6231, Fax +965 25338905, Email Background and Aim: There is noticeable heterogeneity in weight loss outcomes following intragastric balloon (IGB) treatment, with average weight loss ranging between 11% to 15% of total body weight. Genetic variations associated with obesity have been found to influence weight loss response, however such variations are limited. Therefore, the aim of this study is to investigate the impact of the obesity associated brain-derived neurotrophic factor (BDNF) gene polymorphism rs11030104 with weight loss outcomes following IGB treatment. Methods: In this cross-sectional study, BDNF rs11030104 was analysed in 106 individuals who underwent intragastric balloon treatment. Weight loss metrics were evaluated at the three-month follow-up: percentage of total weight loss (%TWL), percentage of excess weight loss (%EWL), and percentage of body mass index loss (%EBMIL). The effects of additive and dominant genetic models were evaluated. Both linear and logistic regression were applied to assess associations between rs11030104 genotypes and weight loss metrics. Results: A total of 71 participants completed the 3-month follow-up assessment (loss to follow-up: 33%). This study found a significant association between the BDNF rs11030104 polymorphism and weight loss. A-allele carriers showed a better response to IGB treatment. Individuals carrying the AA genotype were found to have a greater %TWL than those carrying the GG genotype at 3 months post-IGB treatment (11.05% vs 5.09%, p=0.003). Conclusion: Our results suggest that BDNF rs11030104 influences the response to weight loss after IGB treatment and therefore could be added to the growing list of genetic variants that predict greater weight loss response. Keywords: BDNF, polymorphism, obesity, intragastric balloon, BMI, weight loss The rate of obesity is increasing at an alarming pace, with certain populations exceeding 50%. According to the world health organization, obesity has doubled in adults and quadrupled in adolescents since 1990. 1 This significant increase has resulted in an urgency to develop treatments for the management of obesity. 2 Among these treatments, medical and surgical devices have become widely available through the use of a variety of techniques and procedures. 3 The intragastric balloon (IGB) is an FDA-approved minimally invasive intervention for weight loss that has been widely used. 4 The implantation of the IGB in the stomach for a specified period of time reduces the stomach capacity. This mechanistic approach provides a sensation of satiety leading to the consumption of smaller meals and, in turn, results in weight loss. 5,6 A meta-analysis of 40,000 subjects showed that IGB treatment resulted in weight loss between 11% and 15% of total body weight at the 6-month follow-up. 7 In addition, several randomized clinical trials have shown that IGB is an effective treatment option for the management of obesity. In particular, compared with conventional treatments, IGB has been shown to cause significant weight loss in combination with lifestyle modifications. 8,9 Although weight loss is observed among patients undergoing IGB, interindividual variation in weight loss is evident. For instance, a meta-analysis reported that weight loss among IGB patients varied widely, where treatment resulted in no weight loss or extreme weight loss in some patients, reaching up to 87.5 kilograms (kg). 7,10 Heterogeneity in weight loss is broadly attributed to well-established lifestyle factors, such as the level of physical activity and caloric intake. 11 In addition to lifestyle factors, genetics also contributes to weight loss outcomes after treatment. 12 Genetic variations associated with obesity have been shown to influence weight loss among individuals undergoi -Abstract Truncated-
endocrinology & metabolism